![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib inPatients with Metastatic Triple Negative Breast Cancer
This clinical trial is evaluating the safety and whether this combination therapy using Eribulin and Copanlisib stops cancer growth in patients with metastatic triple-negative breast cancer. Eribulin is a type of chemotherapy drug that is commonly used to treat metastatic breast cancer, while Copanlisib is a targeted therapy that inhibits the PI3K pathway, which is often activated in triple-negative breast cancer. The trial is investigating whether the combination of these two drugs can improve treatment outcomes in this patient population.
Metastatic: cancer that has spread from its original location or organ to other parts of the body. |
Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors. |
For more information about the trial, click the link below:
https://clinicaltrials.gov/ct2/show/NCT04345913 NCI-2020-02319
Clinical Trial Site: Columbia
To see all available clinical trials click here.
Comments